Prevalence and Outcome of Secondary Hemophagocytic Lymphohistiocytosis Among SIRS Patients: Results from a Prospective Cohort Study

Secondary hemophagocytic lymphohistiocytosis (sHLH) is a life-threatening condition clinically presenting as SIRS (Systemic Inflammatory Response Syndrome). However, there is no comprehensive data concerning diagnostic algorithms, prevalence, outcome and biomarker performance in SIRS patients. We co...

Full description

Saved in:
Bibliographic Details
Published in:Journal of clinical medicine Vol. 8; no. 4; p. 541
Main Authors: Gualdoni, Guido A, Hofmann, Georg A, Wohlfarth, Philipp, Winkler, Heide-Maria, Winkler, Stefan, Haslacher, Helmuth, Thalhammer, Renate, Makristathis, Athanasios, Ratzinger, Franz, Burgmann, Heinz
Format: Journal Article
Language:English
Published: Switzerland MDPI 19-04-2019
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Abstract Secondary hemophagocytic lymphohistiocytosis (sHLH) is a life-threatening condition clinically presenting as SIRS (Systemic Inflammatory Response Syndrome). However, there is no comprehensive data concerning diagnostic algorithms, prevalence, outcome and biomarker performance in SIRS patients. We conducted a prospective observational cohort study on 451 consecutive patients fulfilling ≥2 SIRS criteria. The Hscore and the HLH-2004 criteria were used to determine the presence of sHLH, and the correlation of the screening-biomarkers ferritin, sCD25, and sCD163 with both scores was assessed. Out of 451 standard-care SIRS patients, five patients had high Hscores (≥169), suggesting incipient or HLH-like disease, and these patients were in urgent need for intensified therapy. However, none of these patients fulfilled five HLH-2004 criteria required for formal diagnosis. From the studied biomarkers, ferritin correlated strongest to both the HLH-2004 criteria and the Hscore (rs = 0.72, 0.41, respectively), and was the best predictor of 30-day survival (HR:1.012 per 100 μg/L, 95% CI: 1.004-1.021), when adjusted for patient's age, sex, bacteremia and malignant underlying-disease. Also, the HLH-2004 (HR per point increase: 1.435, 95% CI: 1.1012-2.086) and the Hscore (HR per point increase:1.011, 95% CI: 1.002-1.020) were independent predictors of 30-day-survival. The Hscore detected patients in hyperinflammatory states requiring urgent therapy escalation. Degrees of hyperinflammation, as assessed by ferritin and both HLH scores, are associated with worse outcomes.
AbstractList Secondary hemophagocytic lymphohistiocytosis (sHLH) is a life-threatening condition clinically presenting as SIRS (Systemic Inflammatory Response Syndrome). However, there is no comprehensive data concerning diagnostic algorithms, prevalence, outcome and biomarker performance in SIRS patients. We conducted a prospective observational cohort study on 451 consecutive patients fulfilling ≥2 SIRS criteria. The Hscore and the HLH-2004 criteria were used to determine the presence of sHLH, and the correlation of the screening-biomarkers ferritin, sCD25, and sCD163 with both scores was assessed. Out of 451 standard-care SIRS patients, five patients had high Hscores (≥169), suggesting incipient or HLH-like disease, and these patients were in urgent need for intensified therapy. However, none of these patients fulfilled five HLH-2004 criteria required for formal diagnosis. From the studied biomarkers, ferritin correlated strongest to both the HLH-2004 criteria and the Hscore (rs = 0.72, 0.41, respectively), and was the best predictor of 30-day survival (HR:1.012 per 100 μg/L, 95% CI: 1.004–1.021), when adjusted for patient’s age, sex, bacteremia and malignant underlying-disease. Also, the HLH-2004 (HR per point increase: 1.435, 95% CI: 1.1012–2.086) and the Hscore (HR per point increase:1.011, 95% CI: 1.002–1.020) were independent predictors of 30-day-survival. The Hscore detected patients in hyperinflammatory states requiring urgent therapy escalation. Degrees of hyperinflammation, as assessed by ferritin and both HLH scores, are associated with worse outcomes.
Author Gualdoni, Guido A
Hofmann, Georg A
Haslacher, Helmuth
Thalhammer, Renate
Burgmann, Heinz
Wohlfarth, Philipp
Makristathis, Athanasios
Winkler, Heide-Maria
Winkler, Stefan
Ratzinger, Franz
AuthorAffiliation 3 Division of Bone Marrow Transplantation, Department of Medicine I, Medical University of Vienna, 1090 Vienna, Austria; Philipp.wohlfarth@meduniwien.ac.at
4 Department of Laboratory Medicine, Medical University of Vienna, 1090 Vienna, Austria; Helmuth.haslacher@meduniwien.ac.at (H.H.); renate.thalhammer@meduniwien.ac.at (R.T.); Athanasios.Makristathis@meduniwien.ac.at (A.M.)
2 Division of Nephrology and Dialysis, Department of Medicine III, Medical University of Vienna, 1090 Vienna, Austria
1 Division of Infectious Diseases and Tropical Medicine, Department of Medicine I, Medical University of Vienna, 1090 Vienna, Austria; guido.gualdoni@meduniwien.ac.at (G.A.G.); n1203609@students.meduniwien.ac.at (G.A.H.); heide-maria.winkler@meduniwien.ac.at (H.-M.W.); stefan.winkler@meduniwien.ac.at (S.W.); heinz.burgmann@meduniwien.ac.at (H.B.)
AuthorAffiliation_xml – name: 4 Department of Laboratory Medicine, Medical University of Vienna, 1090 Vienna, Austria; Helmuth.haslacher@meduniwien.ac.at (H.H.); renate.thalhammer@meduniwien.ac.at (R.T.); Athanasios.Makristathis@meduniwien.ac.at (A.M.)
– name: 1 Division of Infectious Diseases and Tropical Medicine, Department of Medicine I, Medical University of Vienna, 1090 Vienna, Austria; guido.gualdoni@meduniwien.ac.at (G.A.G.); n1203609@students.meduniwien.ac.at (G.A.H.); heide-maria.winkler@meduniwien.ac.at (H.-M.W.); stefan.winkler@meduniwien.ac.at (S.W.); heinz.burgmann@meduniwien.ac.at (H.B.)
– name: 2 Division of Nephrology and Dialysis, Department of Medicine III, Medical University of Vienna, 1090 Vienna, Austria
– name: 3 Division of Bone Marrow Transplantation, Department of Medicine I, Medical University of Vienna, 1090 Vienna, Austria; Philipp.wohlfarth@meduniwien.ac.at
Author_xml – sequence: 1
  givenname: Guido A
  surname: Gualdoni
  fullname: Gualdoni, Guido A
  email: guido.gualdoni@meduniwien.ac.at, guido.gualdoni@meduniwien.ac.at
  organization: Division of Nephrology and Dialysis, Department of Medicine III, Medical University of Vienna, 1090 Vienna, Austria. guido.gualdoni@meduniwien.ac.at
– sequence: 2
  givenname: Georg A
  surname: Hofmann
  fullname: Hofmann, Georg A
  email: n1203609@students.meduniwien.ac.at
  organization: Division of Infectious Diseases and Tropical Medicine, Department of Medicine I, Medical University of Vienna, 1090 Vienna, Austria. n1203609@students.meduniwien.ac.at
– sequence: 3
  givenname: Philipp
  surname: Wohlfarth
  fullname: Wohlfarth, Philipp
  email: Philipp.wohlfarth@meduniwien.ac.at
  organization: Division of Bone Marrow Transplantation, Department of Medicine I, Medical University of Vienna, 1090 Vienna, Austria. Philipp.wohlfarth@meduniwien.ac.at
– sequence: 4
  givenname: Heide-Maria
  surname: Winkler
  fullname: Winkler, Heide-Maria
  email: stefan.winkler@meduniwien.ac.at
  organization: Division of Infectious Diseases and Tropical Medicine, Department of Medicine I, Medical University of Vienna, 1090 Vienna, Austria. stefan.winkler@meduniwien.ac.at
– sequence: 5
  givenname: Stefan
  surname: Winkler
  fullname: Winkler, Stefan
  email: stefan.winkler@meduniwien.ac.at
  organization: Division of Infectious Diseases and Tropical Medicine, Department of Medicine I, Medical University of Vienna, 1090 Vienna, Austria. stefan.winkler@meduniwien.ac.at
– sequence: 6
  givenname: Helmuth
  surname: Haslacher
  fullname: Haslacher, Helmuth
  email: Helmuth.haslacher@meduniwien.ac.at
  organization: Department of Laboratory Medicine, Medical University of Vienna, 1090 Vienna, Austria. Helmuth.haslacher@meduniwien.ac.at
– sequence: 7
  givenname: Renate
  surname: Thalhammer
  fullname: Thalhammer, Renate
  email: renate.thalhammer@meduniwien.ac.at
  organization: Department of Laboratory Medicine, Medical University of Vienna, 1090 Vienna, Austria. renate.thalhammer@meduniwien.ac.at
– sequence: 8
  givenname: Athanasios
  surname: Makristathis
  fullname: Makristathis, Athanasios
  email: Athanasios.Makristathis@meduniwien.ac.at
  organization: Department of Laboratory Medicine, Medical University of Vienna, 1090 Vienna, Austria. Athanasios.Makristathis@meduniwien.ac.at
– sequence: 9
  givenname: Franz
  surname: Ratzinger
  fullname: Ratzinger, Franz
  email: ranz.ratzinger@meduniwien.ac.at
  organization: Department of Laboratory Medicine, Medical University of Vienna, 1090 Vienna, Austria. ranz.ratzinger@meduniwien.ac.at
– sequence: 10
  givenname: Heinz
  surname: Burgmann
  fullname: Burgmann, Heinz
  email: heinz.burgmann@meduniwien.ac.at
  organization: Division of Infectious Diseases and Tropical Medicine, Department of Medicine I, Medical University of Vienna, 1090 Vienna, Austria. heinz.burgmann@meduniwien.ac.at
BackLink https://www.ncbi.nlm.nih.gov/pubmed/31010216$$D View this record in MEDLINE/PubMed
BookMark eNpVkd9rFDEQx4NUbK198Q-QPIpwml97yfkglENt4aBHT59DNpncpmw2a5I9uGf_cbe01jovM8x8-M4M39foZEgDIPSWko-cr8inOxsVEaQR9AU6Y0TKBeGKnzyrT9FFKXdkDqUEo_IVOuWUUMLo8gz93mY4mB4GC9gMDt9M1aYIOHm8A5sGZ_IRX0FMY2f2yR5rsHhzjGOXulBquO-kEgq-jGnY49317Q5vTQ0w1PIZ30KZ-lqwzylig7c5lRFsDQfA69SlXPGuTu74Br30pi9w8ZjP0c9vX3-srxabm-_X68vNwnKp6sJ5qTwnkgjXECeoVJL51kqmDLfglGodIWJFlVxS14D3Qljm2tYY5YVbWn6OvjzojlMbwdn5yGx6PeYQ5y91MkH_PxlCp_fpoJcNVbRhs8D7R4Gcfk1Qqo6hWOh7M0CaimaM8plbqWZGPzygdn66ZPBPayjR98bpf8bN8Lvnhz2hf23ifwAID5kV
CitedBy_id crossref_primary_10_3389_fimmu_2020_00524
crossref_primary_10_1371_journal_pone_0253894
crossref_primary_10_2147_IDR_S408198
crossref_primary_10_1371_journal_pone_0267715
crossref_primary_10_1016_j_retram_2023_103430
crossref_primary_10_1186_s13054_020_02941_3
crossref_primary_10_1007_s00277_020_04083_6
crossref_primary_10_1080_07853890_2022_2149850
crossref_primary_10_7759_cureus_31969
crossref_primary_10_1159_000536287
crossref_primary_10_1016_j_ajem_2020_03_017
crossref_primary_10_5005_jp_journals_10071_24136
Cites_doi 10.1002/art.38690
10.1111/ped.13064
10.1038/srep40646
10.1016/S0272-2712(18)30132-X
10.1016/j.blre.2016.05.001
10.3109/03009742.2016.1167951
10.1016/S1473-3099(07)70290-6
10.1097/CCM.0000000000001402
10.1007/s12185-015-1813-1
10.1016/j.critrevonc.2017.03.023
10.1007/s00277-017-2993-y
10.1016/j.cmi.2015.11.018
10.1016/j.amjmed.2014.04.034
10.1097/CCM.0000000000001878
10.1016/j.reuma.2014.06.007
10.1038/s41598-018-30236-9
10.1186/1741-7015-11-185
10.1378/chest.101.6.1644
10.1111/imj.12768
10.2307/2532740
10.1016/j.coi.2017.08.004
10.1182/bloodadvances.2017012310
10.1097/BOR.0b013e32834dd37e
10.1002/pbc.21039
10.3324/haematol.2013.097394
10.1097/BOR.0000000000000093
10.3109/10428194.2010.551153
10.1182/asheducation-2013.1.605
10.1182/blood-2014-10-602607
10.1097/PCC.0b013e3181a1ae08
10.1007/s00277-015-2523-8
10.1111/j.1600-0609.2004.00318.x
10.1002/art.22416
10.1002/ajh.1141
10.1089/bio.2018.0032
10.1177/0885066617711386
10.1371/journal.pone.0082946
10.1186/s12916-017-0930-5
10.1309/AJCPMD5TJEFOOVBW
10.1186/cc10073
ContentType Journal Article
Copyright 2019 by the authors. 2019
Copyright_xml – notice: 2019 by the authors. 2019
DBID NPM
AAYXX
CITATION
7X8
5PM
DOI 10.3390/jcm8040541
DatabaseName PubMed
CrossRef
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle PubMed
CrossRef
MEDLINE - Academic
DatabaseTitleList CrossRef

PubMed
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 2077-0383
ExternalDocumentID 10_3390_jcm8040541
31010216
Genre Journal Article
GroupedDBID 53G
5VS
7X7
8FI
8FJ
AADQD
AAFWJ
ABDBF
ABUWG
ADBBV
AFKRA
AFZYC
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
BCNDV
BENPR
CCPQU
DIK
FYUFA
GROUPED_DOAJ
HMCUK
HYE
IAO
IHR
ITC
KQ8
M48
MODMG
M~E
NPM
OK1
PGMZT
PIMPY
RPM
UKHRP
AAYXX
CITATION
7X8
5PM
AFPKN
ID FETCH-LOGICAL-c378t-df78f30704d50d417872fbc728a3ced88bd004918761d5eff44c2dbbaa8f4d6c3
IEDL.DBID RPM
ISSN 2077-0383
IngestDate Tue Sep 17 21:25:16 EDT 2024
Fri Oct 25 00:31:40 EDT 2024
Thu Nov 21 20:38:54 EST 2024
Wed Oct 16 00:49:01 EDT 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 4
Keywords SIRS
hemophagocytosis
prevalence
HLH
survival
hemophagocytic lymphohistiocytosis
outcome
Language English
License Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c378t-df78f30704d50d417872fbc728a3ced88bd004918761d5eff44c2dbbaa8f4d6c3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ORCID 0000-0001-9490-0197
OpenAccessLink https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6518152/
PMID 31010216
PQID 2213152985
PQPubID 23479
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_6518152
proquest_miscellaneous_2213152985
crossref_primary_10_3390_jcm8040541
pubmed_primary_31010216
PublicationCentury 2000
PublicationDate 20190419
PublicationDateYYYYMMDD 2019-04-19
PublicationDate_xml – month: 4
  year: 2019
  text: 20190419
  day: 19
PublicationDecade 2010
PublicationPlace Switzerland
PublicationPlace_xml – name: Switzerland
PublicationTitle Journal of clinical medicine
PublicationTitleAlternate J Clin Med
PublicationYear 2019
Publisher MDPI
Publisher_xml – name: MDPI
References ref13
ref35
ref12
ref34
ref15
ref14
ref36
Kleynberg (ref4) 2012; 10
ref31
ref30
ref11
ref33
ref10
ref32
ref2
ref1
ref17
ref39
ref16
ref38
ref19
ref18
ref24
ref23
ref26
ref25
ref20
ref42
ref22
ref21
ref43
Emmenegger (ref37) 2002; 132
Goel (ref41) 2012; 42
ref28
ref27
ref29
ref8
ref7
ref9
ref3
ref6
ref5
ref40
References_xml – ident: ref10
  doi: 10.1002/art.38690
– ident: ref5
  doi: 10.1111/ped.13064
– ident: ref23
  doi: 10.1038/srep40646
– volume: 42
  start-page: 21
  year: 2012
  ident: ref41
  article-title: Sensitivity and specificity of bone marrow hemophagocytosis in hemophagocytic lymphohistiocytosis
  publication-title: Ann. Clin. Lab. Sci.
  contributor:
    fullname: Goel
– ident: ref2
  doi: 10.1016/S0272-2712(18)30132-X
– ident: ref7
  doi: 10.1016/j.blre.2016.05.001
– ident: ref9
  doi: 10.3109/03009742.2016.1167951
– ident: ref34
  doi: 10.1016/S1473-3099(07)70290-6
– ident: ref30
  doi: 10.1097/CCM.0000000000001402
– ident: ref36
  doi: 10.1007/s12185-015-1813-1
– ident: ref16
  doi: 10.1016/j.critrevonc.2017.03.023
– ident: ref11
  doi: 10.1007/s00277-017-2993-y
– ident: ref35
  doi: 10.1016/j.cmi.2015.11.018
– ident: ref19
  doi: 10.1016/j.amjmed.2014.04.034
– ident: ref12
  doi: 10.1097/CCM.0000000000001878
– ident: ref28
  doi: 10.1016/j.reuma.2014.06.007
– ident: ref24
  doi: 10.1038/s41598-018-30236-9
– ident: ref32
  doi: 10.1186/1741-7015-11-185
– ident: ref25
  doi: 10.1378/chest.101.6.1644
– ident: ref13
  doi: 10.1111/imj.12768
– ident: ref27
  doi: 10.2307/2532740
– ident: ref1
  doi: 10.1016/j.coi.2017.08.004
– ident: ref40
  doi: 10.1182/bloodadvances.2017012310
– ident: ref33
  doi: 10.1097/BOR.0b013e32834dd37e
– ident: ref8
  doi: 10.1002/pbc.21039
– ident: ref20
  doi: 10.3324/haematol.2013.097394
– ident: ref21
  doi: 10.1097/BOR.0000000000000093
– ident: ref29
  doi: 10.3109/10428194.2010.551153
– ident: ref3
  doi: 10.1182/asheducation-2013.1.605
– ident: ref39
  doi: 10.1182/blood-2014-10-602607
– ident: ref17
  doi: 10.1097/PCC.0b013e3181a1ae08
– ident: ref43
  doi: 10.1007/s00277-015-2523-8
– volume: 10
  start-page: 726
  year: 2012
  ident: ref4
  article-title: Secondary hemophagocytic lymphohistiocytosis in adults: An update on diagnosis and therapy
  publication-title: Clin. Adv. Hematol. Oncol.
  contributor:
    fullname: Kleynberg
– ident: ref14
  doi: 10.1111/j.1600-0609.2004.00318.x
– ident: ref15
  doi: 10.1002/art.22416
– ident: ref38
  doi: 10.1002/ajh.1141
– ident: ref26
  doi: 10.1089/bio.2018.0032
– volume: 132
  start-page: 230
  year: 2002
  ident: ref37
  article-title: Reactive macrophage activation syndrome: A simple screening strategy and its potential in early treatment initiation
  publication-title: Swiss Med. Wkly.
  contributor:
    fullname: Emmenegger
– ident: ref6
  doi: 10.1177/0885066617711386
– ident: ref22
  doi: 10.1371/journal.pone.0082946
– ident: ref31
  doi: 10.1186/s12916-017-0930-5
– ident: ref42
  doi: 10.1309/AJCPMD5TJEFOOVBW
– ident: ref18
  doi: 10.1186/cc10073
SSID ssj0000884217
Score 2.2132647
Snippet Secondary hemophagocytic lymphohistiocytosis (sHLH) is a life-threatening condition clinically presenting as SIRS (Systemic Inflammatory Response Syndrome)....
SourceID pubmedcentral
proquest
crossref
pubmed
SourceType Open Access Repository
Aggregation Database
Index Database
StartPage 541
Title Prevalence and Outcome of Secondary Hemophagocytic Lymphohistiocytosis Among SIRS Patients: Results from a Prospective Cohort Study
URI https://www.ncbi.nlm.nih.gov/pubmed/31010216
https://search.proquest.com/docview/2213152985
https://pubmed.ncbi.nlm.nih.gov/PMC6518152
Volume 8
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Nb9NAEB2RHhAXxDehUA2Cq5va3o033KrQKhUUogYkbtZ6P0hQ443i-JBz_zgzdlwauHG1vStr3-zOG-3MG4D33FK7iL2OvDrRkbB8DnqhI5PGnFHpdJZy7fBkln35oT6esUyO7GphmqR9UyyOy-vlcbmYN7mVq6UZdHlig-nleCjJL8lk0IMeccM7IXpz_ColiGe3UqQphfSDX2apyFal4LYwRGe4m_Vw3w_9Qy7_zpG843TOH8HDHVvE0_avHsM9Vz6B-5e7-_CncMMKTLqpG0JdWvxab8iCHAaPM450rV5vceKWYTXXP4PZ0jT4eUsABtYZXvCTUC0qPOWWQzi7uJrhtBVarT7glavq602FXIGCGqfr0JVl4jjMibYjJyFun8H387Nv40m0a6tAAGRqE1mfKc9bXVh5YkVMWzbxhckSpVPjrFKF5bghpnMyttJ5L4RJbFFoTSjaoUmfw0EZSvcS0KiCHL7wsU64h7EaySyTRUpBi7Ujndo-vOsWOV-16hk5RR2MSv4HlT687dY_J-PmGwtdulBXeZLEKQE9UrIPL1o8bufpgOxDtofU7QcsnL3_huypEdDe2c-r_x55CA-IODW3SvHoNRxs1rV7A73K1kdEyy8-HTUm-RtlbunF
link.rule.ids 230,315,729,782,786,887,27933,27934,53800,53802
linkProvider National Library of Medicine
linkToHtml http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Nb9NAEB3RIgGXlq_SUAqL4OomtnfjDbcqtEpFUqKmSNys9X6QoMYbxfEhZ_44M3ZcmnLr1etdWX6zs2-0M28APlNL7Sx0KnCyowJuyA86rgIdh5RRaVUSU-3wYJJc_pRfz0gmRzS1MFXSvs5mJ_nN_CSfTavcysVct5s8sfZ41O8KPJdE1N6Bx7hfO507QXrlgKXkyLRrMdIYg_r2bz2XaK2CU2MYJDTUz7q7fRL9Ry_vZ0neOXbO9x_4wc9hb8Mz2Wk9_AIe2fwlPBltbtJfwR_SblJVxRFTuWHfyxXanmXesQnFyEYt12xg534xVb-8XuMybLhG6D0pFM_oiS9mBTulZkVscnE1YeNaorX4wq5sUd6sCka1K0yx8dI3BZ2s76dI-BmlL65fw4_zs-v-INg0ZEDoErkKjEukIyfBjegYHuJmj1ymk0iqWFsjZWYo4gjRw4ZGWOc415HJMqUQf9PV8QHs5j63h8C0zJAqcBeqiLofy55IEpHFGO4Y01OxacGnBpx0UetupBivEJrpPzRb8LHBLcVtQXcdKre-LNIoCmP84z0pWvCmxvF2ncYAWpBsIXz7Aklub48gsJX09gbItw-e-QGeDq5Hw3R4cfntCJ4h_arupsLeO9hdLUt7DDuFKd9XBv0XpSj-UA
linkToPdf http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LT9tAEB4VKqFe-i5NaelW9Goc2-t4ww0FoqDyiEgr9Wat90GCiDeK40PO_HFm7Dgl5dZe7d2V5W92dkY7830A30lSOwus9KxoS49r8oOWS09FAVVUGplE1Ds8GCWXv8XJKdHkrKW-qqJ9lU0O87vpYT4ZV7WVs6nymzoxf3jR68R4LsWhP9PW34LnuGfb4aNEvXLCQnCMtmtC0ggTe_9WTQVabMxJHAaDGtK07myeRk9CzL8rJR8dPf1X__HRr-HlKt5kx_WQN_DM5G9h52J1o_4O7onDSVadR0zmml2VC7RBw5xlI8qVtZwv2cBM3Wwsb5xa4jLsfIkm4IipeEJPXDEp2DGJFrHR2fWIDWuq1uKIXZuivFsUjHpYmGTDuWsaO1nPjTHwZ1TGuHwPv_qnP3sDbyXMgBAmYuFpmwhLzoLruK15gJs-tJlKQiEjZbQQmabMI0BPG-jYWMu5CnWWSYl2oDsq-gDbucvNR2BKZBgycBvIkFSQRTdOkjiLMO3Ruisj3YKDBqB0VvNvpJi3EKLpH0Rb8K3BLsXtQXceMjeuLNIwDCL8610Rt2C3xnK9TmMELUg2UF4PIOrtzTcIbkXBvQLz0z_P_Ao7w5N-en52-WMPXmAUVl1RBd3PsL2Yl-YLbBW63K9s-gGRUgDf
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Prevalence+and+Outcome+of+Secondary+Hemophagocytic+Lymphohistiocytosis+Among+SIRS+Patients%3A+Results+from+a+Prospective+Cohort+Study&rft.jtitle=Journal+of+clinical+medicine&rft.au=Gualdoni%2C+Guido+A&rft.au=Hofmann%2C+Georg+A&rft.au=Wohlfarth%2C+Philipp&rft.au=Winkler%2C+Heide-Maria&rft.date=2019-04-19&rft.issn=2077-0383&rft.eissn=2077-0383&rft.volume=8&rft.issue=4&rft_id=info:doi/10.3390%2Fjcm8040541&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2077-0383&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2077-0383&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2077-0383&client=summon